Trial finds neither azithromycin nor doxycycline meaningfully improve recovery times or reduce risk of hospitalisation in non-hospitalised COVID-19 patients.
List view / Grid view
Filter the results
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
The COVID-19 European Medicines Agency (EMA) pandemic Task Force (COVID-ETF) warned that chloroquine and hydroxychloroquine are yet to be proved effective at treating COVID-19 and that their side effects could be fatal.
The PRINCIPLE trial aims to evaluate therapeutics that could slow the progression of COVID-19 symptoms in patients most at risk of complications.
Zoliflodacin was found to be effective in curing all rectal gonorrheal infections in patients during a Phase II clinical trial...
Scientists show how the gonorrhoea bacterium resists last-resort antibiotic ceftriaxone while maintaining a robust growth rate...
Treating people who start HIV treatment late with a package of low-cost drugs to prevent serious infections saves three lives for ...